Compare STRS & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STRS | ADAG |
|---|---|---|
| Founded | 1992 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.9M | 254.4M |
| IPO Year | 1994 | 2020 |
| Metric | STRS | ADAG |
|---|---|---|
| Price | $28.31 | $3.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 30.2K | ★ 132.2K |
| Earning Date | 05-14-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 512.50 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $29,914,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.87 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.35 | $1.44 |
| 52 Week High | $32.93 | $4.75 |
| Indicator | STRS | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 36.57 | 52.63 |
| Support Level | $28.22 | $3.31 |
| Resistance Level | $31.37 | $3.99 |
| Average True Range (ATR) | 0.82 | 0.33 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 15.49 | 57.26 |
Stratus Properties Inc is a diversified real estate company operating in the United States. It is engaged in the entitlement, development, management, leasing, and sale of multi-family and single-family residential and commercial real estate properties in the Austin, Texas area and other select markets in Texas. The company operates in two reportable segments: Real Estate Operations and Leasing Operations. Maximum revenue is generated from the Leasing Operations segment, which involves the leasing of commercial and residential properties developed by the company. The Real Estate Operations segment comprises properties under various stages of development: developed for sale, under development, and available for development.
Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.